Glenmark Pharmaceuticals Limited – FDA 483, Apr 20, 2019
Glenmark Pharmaceuticals Limited in Baddi, India, received an FDA Form 483 citing significant deficiencies across multiple areas of its finished drug manufacturing operations. The inspection revealed failures in thorough investigations of product discrepancies, inadequate stability testing, and a lack of robust process validation and equipment cleaning procedures. Additionally, issues with employee training, field alert reporting, laboratory controls, and document management were identified, indicating systemic quality control concerns.
ID · b7ff58c7-f479-4ebb-a95a-ce9b1c103a62
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.